Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 266
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P22F8A1E6D7EN
Leaflet:

Download PDF Leaflet

Pulmonary Arterial Hypertension - Pipeline Review, H2 2017
Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Pulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Therapeutics Development
Pulmonary Arterial Hypertension - Therapeutics Assessment
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Pulmonary Arterial Hypertension - Drug Profiles
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2017
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Company, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Savara Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2017
Pulmonary Arterial Hypertension - Dormant Projects, H2 2017
Pulmonary Arterial Hypertension - Dormant Projects, H2 2017 (Contd..1), H2 2017
Pulmonary Arterial Hypertension - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Actelion Ltd
Aerogen Ltd
Arena Pharmaceuticals Inc
Ascendis Pharma A/S
Asklepion Pharmaceuticals LLC
AVEO Pharmaceuticals Inc
Bial - Portela & Ca SA
Biogen Inc
Bristol-Myers Squibb Company
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chugai Pharmaceutical Co Ltd
Complexa Inc
Eli Lilly and Company
Galectin Therapeutics Inc
GlaxoSmithKline Plc
HitGen LTD
Insmed Inc
Insys Therapeutics Inc
Johnson & Johnson
Liquidia Technologies Inc
MannKind Corp
Mezzion Pharma Co Ltd
Nippon Kayaku Co Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Industries Ltd
Northern Therapeutics Inc
Novartis AG
Peloton Therapeutics Inc
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Polyphor Ltd
Pulmokine Inc
Reata Pharmaceuticals Inc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
Savara Inc
Serodus ASA
Silence Therapeutics Plc
SteadyMed Therapeutics Inc
Suda Ltd
Takeda Pharmaceutical Company Ltd
Toray Industries Inc
United Therapeutics Corp
Vicore Pharma AB
Vivus Inc
Skip to top


Ask Your Question

Pulmonary Arterial Hypertension - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: